Aspirin Prophylaxis in Sickle Cell Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

April 30, 2009

Study Completion Date

November 30, 2009

Conditions
Sickle Cell Disease
Interventions
DRUG

aspirin

81 mg flavored chewable tablets. Subjects between the ages of 2.0 and 4.99 years will receive half of an 81 mg aspirin tablet each day. Those older than 5.0 years will receive a daily 81 mg aspirin tablet. The subject will receive the study drug for a period of 12 months.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of Miami

OTHER

collaborator

Bayer

INDUSTRY

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

University of Rochester

OTHER